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
This paper reports the anti-cryptosporidial effects of, and concomitant amelioration of the histological changes in the gut
of neonatal rats with intestinal cryptosporidiosis treated with the dinitroaniline, oryzalin. The ED
&!
was determined to be
7 mg}kg using twice daily doses administered for 3 consecutive days. A maximum inhibition of 85±5% was achieved at
25 mg}kg and this inhibition remained constant despite increasing the oryzalin dose to 200 mg}kg. Cryptosporidiosis
significantly decreased the intestinal villus}crypt (VC) ratio by approximately 50% (duodenum¯2±3, jejunum¯2±5 and
ileum¯1±7) when compared to uninfected untreated controls (duodenum¯4±3, jejunum¯5±9 and ileum¯4±5). Treat-
ment with oryzalin doubled the VC ratio in the duodenum, jejunum and ileum following doses of 5 mg, 50 mg and
200 mg}kg respectively. Oryzalin concentrations in the small intestine contents and plasma were determined, using HPLC,
at 0±5, 1 and 2 h after dosing. The much greater dose required to return VC ratios to normal in the ileum (200 mg}kg)
compared to the duodenum (6±25 mg}kg) appeared to reflect the decreased concentration of the drug in the distal small
intestine. Concentrations of oryzalin equivalent to the in vitro IC
&!
were maintained for 2 h in the first half of the small
intestine following a single dose of 100 mg}kg.
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
An effective anti-cryptosporidial agent is yet to be
found despite the fact that over 200 compounds have
been examined (Woods et al. 1996; Armson et al.
1999a). In the absence of a treatment that is
completely efficacious against C. parvum, a drug that
decreases oocyst numbers and thus parasite pro-
liferation in the gut, concurrently minimizing the
symptoms of this disease must suffice. We have
recently demonstrated the activity of the dinitroani-
line oryzalin in vivo against C. parvum using both a
mouse and a rat model and showed that oryzalin
achieved a 90% inhibition of oocyst numbers using
twice daily doses of 25 mg}kg oryzalin administered
over 3 consecutive days (Armson et al. 1999b).
While there is extensive literature on the in vitro
anti-cryptosporidial effects of the dinitroanilines
(Arrowood et al. 1996; Benbow et al. 1998; Callahan
et al. 1996) there is very little information on the in
vivo effects of this class of compounds (Armson et al.
1999b). This paper follows our previous work on the
in vitro and in vivo effects of the dinitroanilines and
reports on the effects of a range of doses of oryzalin
in infected animals, with respect to anti-parasite
efficacy, histological changes and pharmacokinetics.
The observation that a diminished villus crypt
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(VC) ratio is most severe and more noticeable in the
acute phase of parasitosis enables an assessment of
the relative severity of the disease (Roberts-
Thompson et al. 1976). This can be done by
determining the VC ratio in uninfected, infected
untreated and infected treated animals receiving
different doses of the treatment.
The aims of this study were firstly to determine
the dose-response relationship for oryzalin in the
treatment of murine cryptosporidiosis, secondly to
use the VC ratio to examine the relationship between
gastrointestinal damage caused by cryptosporidial
infection and oryzalin dosage in infected animals,
and lastly to examine the pharmacokinetics of the
drug in neonatal rats. The resultant information will
provide an insight into the efficacy of this drug
against C. parvum.
  
Isolation of infective Cryptosporidium oocysts
A bovine Cryptosporidium isolate was collected from
calf faecal samples using phosphate-buffered saline
(PBS)-ether sedimentation and washing as described
by Morgan, Reynoldson & Thompson (1993).
In vivo analysis of drug activity against
Cryptosporidium
In duplicate experiments resuspended oocysts were
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inoculated into forty 7- to 8-day-old Sprague–
Dawley rats via gastric intubation at a dose rate of
10–12¬10% oocysts per animal, using the method
of Meloni & Thompson (1996). Stock solutions of
drugs were made in 5 ml aliquots. Drugs were dis-
solved in 0±5 ml of dimethyl sulfoxide (Me
#
SO)
which was then added to 4±5 ml peanut oil using a
modification of the method described by Fayer &
Fetterer (1995). On day 4 post-infection, the animals
were weighed and the mean weight for each litter
calculated, allowing for between-litter variation.
Using random numbers 36 rats were randomly
divided into 9 groups of 4 rats. Using the mean
weight, the oryzalin dose rate was determined such
that each group of 4 rats received either 200, 100, 50,
25, 12±5, 6±25 or 3±125 mg}kg of drug in 100 µl
vehicle per rat twice daily for 3 consecutive days.
The remaining 2 groups of 4 rats were controls
including infected untreated and uninfected animals
with both groups receiving drug vehicle alone. All
rats were sacrificed on day 7 post-infection and
processed in the manner described above (Morgan
et al. 1993). Samples were collected into 10%
formaldehyde from the proximal duodenum, mid-
jejunum, terminal ileum, distal caecum and terminal
colon. Routine haematoxylin and eosin-stained
sections were used to evaluate the pathological
changes and measure VC ratios. Remaining gut
contents were processed individually and oocyst load
determined separately. Oocyst production for each
animal was determined by counting the oocysts from
the processed gut following separation using a Ficoll
gradient as described by Meloni & Thompson (1996).
Histological examination of gastrointestinal tract
Samples of duodenum, jejunum, ileum, caecum and
terminal colon were taken from all the rats, either
treated, untreated or control animals for histological
examination. Villus length and crypt depth were
measured in the ileum, jejunum and duodenum and
recorded for all animals. For each anatomical lo-
cation, 20 villi and 20 crypts were measured. The
VC ratios were determined for uninfected untreated,
infected untreated and infected treated animals.
Statistical analysis was performed using hierarchical
and nested analysis of variance (ANOVA) and a one-
way factorial ANOVA with Scheffe! multiple range
test (where P!0±05) using the program JUMP.
Between-group differences and pooled differences
were examined.
Pharmacokinetics using HPLC analysis
A total of sixteen 12- to 14-day-old Sprague–Dawley
rats were dosed with a single oral dose of 100 mg}kg
oryzalin. Groups of 4 rats were sacrificed 0±5, 1, 2
and 3 h following dosing, and the small intestine was
removed and divided into 4 equal lengths. Each
length of intestine was slit longitudinally and placed
into 0±5 ml of PBS. Immediately following death the
animal was exsanguinated by cardiac puncture using
a heparinized syringe in order to obtain plasma drug
concentrations. From each group of 4 animals, 1
animal was used for optimizing the HPLC method.
Samples were then purified for HPLC analysis using
Alltech solid-phase extraction columns according to
the manufacturer’s instructions.
High performance liquid chromatography (HPLC)
A Shimadzu HPLC system consisting of a communi-
cations bus module (CBM-10A), low pressure
gradient valve (FCV-10AL), solvent delivery unit
(LC-10AD), auto-injector (SIL-10A) and UV-VIS
detector (SPD-10AD) connected to a chromato-
graphy work-station (CLASS-LC10) was used for
HPLC. All chromatography was performed using a
150¬3±9 mm Waters Symmetry C8 reverse phase
column and detection of oryzalin was at a wavelength
of 282 nm. The peak area was integrated. The
mobile phase comprised 35% acetonitrile, 30%
methanol and 35% water (v}v) which was filtered
through 0±45 µm filters. The oryzalin retention time
was 4±8 min with a flow rate of 1±5 ml}min. Oryzalin
in test plasma samples was quantified by area using
a spiked plasma standard curve. This limit of
detection was 20 ng}ml.
Sample preparation
The extraction procedure was a modification of the
method of Dvorakova et al. (1997). Plasma samples
were initially extracted on C18 solid-phase extraction
columns (200 mg extract-clean columns – Alltech).
Each column was conditioned with 2 column
volumes of methanol followed by 2 column volumes
of water. Sample extraction was then performed
with 0±5 ml of plasma sample and 1 ml of phosphate
buffer (200 m, pH 7). The column was washed
with 2 ml of 2% acetonitrile and vacuum dried for
2 min prior to elution of the oryzalin with 2 ml of
100% acetonitrile. Samples were then evaporated
dry under nitrogen airflow at 35 °C. The residues
were reconstituted with 200 µl of hexanes and 200 µl
of mobile phase. The samples were then mixed
vigorously for 30 sec and centrifuged at 2000 g for
2 min. A 50 µl aliquot of the lower phase was
removed for HPLC analysis.
All HPLC results were analysed using regression




Oocyst production was measured by counting the
total number of oocysts in the processed gut of each
rat. The oocysts recovered from the treated and
untreated animals were counted on a haemocyto-
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Fig. 1. Effect of oryzalin on the inhibition of oocyst
excretion in mice dosed twice daily for 3 consecutive
days (mean³..).
Fig. 2. Villus height and crypt depth were measured in
the duodenum (E), jejunum (*) and ileum (+) and VC
ratios determined in uninfected rats (U), infected
untreated rats (UI) and infected treated rats receiving
the doses of oryzalin shown (mg}kg) on the horizontal
axis. An asterisk (*) shows where the VC ratio was
significantly different to that of the infected untreated
animal. For multiple comparisons Scheffe! test
significance was used where P!0±05.
meter and the results presented in Fig. 1 expressed
as a percentage inhibition show a steady, almost
linear dose-related reduction up to 25 mg}kg. The
ED
&!
was determined to be 7 mg}kg. A maximum
88±5% reduction was achieved at 25 mg}kg, and
doses up to 200 mg}kg failed to achieve a higher
inhibition of oocyst numbers.
Morphological differences between infected,
uninfected, treated and untreated animals
Although treatment with oryzalin did not completely
eliminate the infection, it was associated with a
Fig. 3. Concentration of oryzalin in the gut was
determined using HPLC. The entire small intestine was
divided into 4 equal segments with segment 1 (*) the
more proximal segment and segment 2 (D) the next,
then segment 3 (+) and segment 4 (E) the more distal




values, determined in vitro for Cryptosporidium
are shown for comparison.
significant reduction in oocyst excretion and the
pathological effects caused by the infection.
Histopathological effects associated with intestinal
cryptosporidiosis included a significant decrease in
VC ratio (Fig. 2) attributable to the combined effects
of villus atrophy and crypt hyperplasia. There was
also a mild increase in inflammatory cells and
fibroplasia within the lamina propria of the small
intestine. The caecal mucosa was attenuated and
there was a decrease in the number of goblet cells.
Lymphoid follicle development within the caecal
mucosa was increased.
Similar changes were observed in infected rats
treated with doses up to 6±25 mg}kg. At doses of
12±5 mg}kg or more there were minimal intestinal
inflammatory changes. In the uninfected animals VC
ratios were 4±3, 5±9 and 4±5 in the duodenum, jejunum
and ileum respectively, whereas in the infected
animals they were reduced to 2±3, 2±5 and 1±7
respectively (Fig. 2). The oryzalin dosage at which
the VC ratios were significantly different (P!0±05)
to those of the untreated infected animals was
12±5 mg}kg or more in the duodenum, 50 mg}kg in
the jejunum and 200 mg}kg in the ileum (Fig. 2). A
concomitant reduction in numbers of oocysts was
noted with increasing dosage.
Numbers of Cryptosporidium stages observed
histologically generally correlated with the degree of
inflammation which was most severe in the caecum.
Inflammatory changes in the caecum resolved once
Cryptosporidium were no longer visible histologi-
cally. Generally the reduction in numbers of goblet
cells associated with Cryptosporidium infection was
reversed with doses of oryzalin of greater than
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Fig. 4. Oryzalin concentration was determined using
HPLC for the small intestine divided into 4 equal
segments. Segment 1 is the proximal segment and
segment 4 is the distal segment. Total oryzalin measured
for each segment is expressed as µg}ml}min and shown
as area under the curve (AUC).
50 mg}kg, which corresponded with a reduction in
Cryptosporidium numbers, although goblet cell num-
bers never returned to those seen in the uninfected
controls.
Pharmacodynamic analysis
Analysis of the concentration of oryzalin in the small
intestine showed that concentrations were higher in
the more proximal segments of intestine (Fig. 3) The
highest concentration (C
max
) was found in the most
proximal segment and this decreased further down
the gut until the more distal segment has a C
max
that
is half that of the more proximal segment. The time
taken to peak concentration (T
max
) was 30 min for all
segments (Fig. 3). The area under the curve (AUC)
for each gut segment is shown in Fig. 4. In terms of
rate of disappearance of oryzalin from the gut
contents, the AUC of the more proximal segment of
intestine was 97 µg}ml}min, in the next segment the
AUC was 20% less than that found in the 1st and in
the 3rd and 4th segments it was just 25% and 10%
respectively of the AUC of the 1st segment.
Regression analysis of the concentration of oryzalin
in the gut at specific times revealed that no significant
differences exist between segments in terms of their
slope (P"0±1) but in terms of elevation or C
max
segments 1 and 2, while not significantly different
from each other, were significantly different from the
C
max
of segments 3 and 4 which were also not
significantly different from one another (P!0±001).
Plasma concentrations of oryzalin remained static
from 30 min to 3 h post-dosing, although wide
variation was noted between animals.

In the absence of a completely efficacious treatment
for cryptosporidiosis, a coccidiostatic compound
presents a real alternative to leaving the infection to
progress unfettered. The dinitroaniline compounds
have proved their anti-cryptosporidial effects in vitro
(Arrowood et al. 1996; Armson et al. 1999a, b)
and in vivo (Armson et al. 1999a, b). The high
inhibition achieved at low dosage in the current
study (50% inhibition at 7±5 mg}kg) suggests that
the promising anti-cryptosporidial effects of oryza-
lin, and possibly other dinitroanilines, in vitro also
occur in vivo, at least in rodents. The large variation
of the oocyst numbers in the treated animals
receiving lower doses of oryzalin is evident although
the variation decreases as the doses increase. The
variation was present in repeat experiments. Whe-
ther this heteroscedasticity is an attribute of the
parasite or the host is unclear in the current study.
Reduction in the small intestinal VC ratio of
infected untreated rats has also been reported
previously in calves, although reduction was much
greater in the current study. VC ratios in infected
rats was less than half that of the uninfected rats,
whereas the ratio in calves infected with the same
parasite was almost 70% that of uninfected calves
(Ruest et al. 1997). This may be a characteristic of
the stage of development of the neonatal rats (7–8
days at time of infection) compared with the calves
or it may be related to the severity of infection which
is likely to alter between species.
The reduction in oocyst numbers as a result of
oryzalin treatment in the current experiments corres-
ponded with a decrease in intestinal inflammation
and improvement in VC ratio. There was a mild
persistence in the reduction of caecal goblet cells
which may be attributable to persistence of low
numbers of Cryptosporidium not detected by his-
tological examination. Alternatively, the experimen-
tal time-scale may have been too short to achieve
complete amelioration of the pathological effects.
The observed increase in crypt mitotic activity in
infected animals is similar to that reported by Harp,
Akili & Pesch (1999) in BALB}c neonatal mice
infected with Cryptosporidium where the prolifer-
ation of cells in the crypt zone of infected mice was
almost twice that of uninfected mice.
A dose-dependent decrease in oocyst numbers was
seen with oryzalin at up to 30 mg}kg at which time
the inhibition reached a plateau. While it is disap-
pointing that higher doses failed to eradicate the
infection completely, they did have an enormous
impact on the severity of the infection in terms of
oocyst numbers and gut pathology. This is best
demonstrated by the dose-dependent increase in VC
ratios, signifying the return of the gut towards the
healthy state. Not surprisingly, the dose of oryzalin
required to return the VC ratios to normal increased
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along the length of the small intestine where
5 mg}kg, 50 mg}kg and 200 mg}kg doses were
required for a doubling of the VC ratios in the
duodenum, jejunum and ileum respectively. The
pharmacodynamic data demonstrated clearly that
the more proximal segments receive the greater
concentrations of the drug. For example, the AUC in
the proximal segment of the small intestine is 10
times that of the most distal segment and the decrease
along the 4 segments approximates a straight line.
Thus the parasites in the more proximal gut are
exposed to significantly greater concentrations of
oryzalin for longer periods of time. This is exempli-




values shown in Fig. 3. Moreover, the IC
&!
value
determined in vitro, 750 n or 0±273 µg}ml, is
maintained in the first 2 segments of the intestine for
2 h after dosing once with 100 mg}kg whereas this
concentration is maintained for no more than 1 h in
the 3rd segment and for just 30 min in the 4th
segment. Thus, the concentration necessary to kill
50% of the parasites is achieved and maintained in
the first half of the gut but is maintained only
transiently in the second half of the gut, resulting in
persistence of the infection. Similarly the IC
*!
is
achieved briefly in the 1st segment of the intestine
only and the minimum lethal concentration (MLC)
is not reached in any segment. Again the inability to
achieve the MLC in the gut is reflected in the failure
to eradicate the infection at high doses. It is
noteworthy that the in vitro IC
&!
is achieved
following a 48 h incubation of the drug. This finding
is in complete agreement with the VC ratios and
distribution of oocysts within the gut.
This study demonstrates that the in vitro activity
of the dinitroaniline oryzalin also occurs in vivo and
further optimization of the drug with regard to
solubility and absorption is required. The oryzalin
concentrations throughout the small intestine sug-
gest that the barrier to successful treatment of
cryptosporidiosis with oryzalin is delivery rather
than poor activity.
Future studies will include chemical changes and
optimization of this family of compounds as well as
altered formulations in order to further decrease the
rate of absorption. In addition, a detailed exam-
ination of the routes of excretion of the compound,
similar to that performed with trifluralin (Erkog &
Menzer, 1985) would be valuable in furthering our
understanding of the disposition of this class of
compounds.
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